Abstract
As a part of the mechanisms of action in reversing FAP adenomas by the low-dose sulindac maintenance therapy (2 x 25 mg/patient per day), the extent of HER-2 proto-oncogene expression in the rectal mucosa seems to be of interest. Immunocytochemical analyses were performed in plasma and in rectal tissue of sulindac-treated FAP patients during an 18 months follow-up and compared with rectal tissue of patients with FAP, Crohn's disease, or rectal cancer or with healthy volunteers. HER-2 was significantly reduced and maintained in tissue under sulindac chemoprevention below base line levels of healthy individuals, but not in plasma. Therefore, a direct or indirect effect of sulindac as a tyrosine kinase inhibitor may be implicated. During NSAID treatment HER-2 protein expression as a prognostic tool seems to be of little clinical relevance.
MeSH terms
-
Adenomatous Polyposis Coli / metabolism*
-
Adenomatous Polyposis Coli / prevention & control*
-
Adolescent
-
Adult
-
Aged
-
Aged, 80 and over
-
Anti-Inflammatory Agents, Non-Steroidal / administration & dosage
-
Anti-Inflammatory Agents, Non-Steroidal / pharmacology*
-
Case-Control Studies
-
Down-Regulation
-
Enzyme Inhibitors / administration & dosage
-
Enzyme Inhibitors / pharmacology*
-
Enzyme-Linked Immunosorbent Assay
-
Female
-
Gene Expression Regulation, Enzymologic
-
Gene Expression Regulation, Neoplastic
-
Humans
-
Intestinal Mucosa / enzymology*
-
Male
-
Middle Aged
-
Protein-Tyrosine Kinases / antagonists & inhibitors*
-
Protein-Tyrosine Kinases / biosynthesis*
-
Proto-Oncogene Mas
-
Receptor, ErbB-2 / biosynthesis*
-
Receptor, ErbB-2 / blood
-
Rectum / enzymology*
-
Sulindac / administration & dosage
-
Sulindac / pharmacology*
Substances
-
Anti-Inflammatory Agents, Non-Steroidal
-
Enzyme Inhibitors
-
MAS1 protein, human
-
Proto-Oncogene Mas
-
Sulindac
-
Protein-Tyrosine Kinases
-
Receptor, ErbB-2